REFERENCES
- Chisari G, Reibaldi M, Sanfilippo M. Validita terapeutica attuale della norfloxacina nelle infezioni oculari esterne. Farmaci e Terapia 2002: XIX; 51-55.
- Jemse HG. In vitro antibiotic susceptibility of ocular iso-lates in North and South America. Cornea 1998; I: 79-87.
- Oomomo A. Pseudomonas aeruginosa ocular infection. Nippon-Risho 1991; 49: 2405–2411.
- Alexandrakis G, Alfonso EC, Miller D. Shifting trend in bacterial keratitis in south Florida and eerging resistance to flu-oroquinolones. Ophthalmology 2000; 107: 1497–1502.
- Everett SL. An in vitro comparison of the susceptibilities of bacterial isolates from patients with conjunctivitis and ble-pharitis to newer and established topical antibiotics. Cornea 1995; 14: 382–392.
- Prosser BT, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 Gram-positive and Gram-negative clinical isolates. Diagn Microbiol Infect Dis 1999; 21; 33–39.
- Osato MS. The comparative in vitro activity of ofloxacin and selected ophhalmic antimicrobial agents against ocular bacterial isolates. Am J Ophthalmol 1998; 108: 380–389.
- Kitano S. Norfloxacin controlled study (multicenter phase III clinical trial on norfloxacin ophthalmic solution: well controlled study). Folia Ophthalmol Jpn 1998; 39: 1151–1159.
- Stenert RF. Current therapy for bacterial keratitis and bacterial conjunctivitis. Am J Ophthalmol 1991; 112–118.
- Chisari G, Reibaldi M, Sanfilippo M. Studio dell'ecosis-tema esterno nei pazienti diabetici con iposecrezione. Ann Ottalmol 2001; CXXVII n.2/3; 113-122.
- Morlet N, Minissian D, Butcher J for the Ofloxacin Study Group. Risk factors for treatment outcome of suspected microbial keratitis. Br J Ophthalmol 1999; 83: 1027–1031.
- Chisari G, Cavallaro G, Reibaldi M, Biondi S. Presurgical antimicrobial prophylaxis: effect on ocular flora in healthy patients. Int J Clin Pharmacol Therapeut 2004; 42: 35–38.
- Chisari G, Reibaldi M, Sanfilippo M. Effect of amino-glycosides (sub-MICS) on adherence of coagulase-negative staphylococci to intraocular lens surface. J Chemother 2002; 14: 640–644.
- Goldestein MH, Kovalski RP, Gordon YJ. Emerging flu-oroquinolone resistance in bacterial keratitis: a 5- year review. Ophthalmology 1999; 106: 1313-1318.
- Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol 1993; 115: 471–477.
- Sinclair NM, Leigh DA. A comparison of fusidic acid viscusus eye drops and chloramphenicol eye ointment in acute conjunctivitis. Curr Ther Res 1998; 44 (3): 468–474.
- Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacteria Keratitis. Am J Ophthalmol 1991; 112-123.
- Nightingale CH. Pharmacokinetic considerations in quinolone therapy. Pharmacocotherapy 1993; 13: 43–54.
- Wolfson JS. The fluoroquinolones: structures, mecha-nisms of actin and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28; 581–595.
- Laibovitz R. Norfloxacinophthalmic solution in acute bacterial conjiunctivitis. Chibret Int J Ophthalmol 1993; 10: 7–21.
- Chisari G, Sanfilippo M, Reibaldi M. Studio clinico-bat-teriologico comparativo tra la ciprofloxacina e la norfloxacina nelle congiuntiviti batteriche. Le Infezioni in Medicina 2003; 1: 25–30.